ERBB2 and breast carcinoma: In this study we employed the Prestwick Chemical Library® with 1200 commonly used drugs for high-throughput screening of compounds that can redirect lysosomes of ErbB2 expressing, 1st line ErbB2-inhibitor resistant breast cancer cells from their invasion-promoting location near the plasma membrane to their less cancerous position at the perinuclear area.